186 related articles for article (PubMed ID: 20799878)
1. Early oncology clinical trial design in the era of molecular-targeted agents.
Brunetto AT; Kristeleit RS; de Bono JS
Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
[TBL] [Abstract][Full Text] [Related]
2. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
3. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Garcia VM; Cassier PA; de Bono J
Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic biomarkers: falling short of the mark?
Gainor JF; Longo DL; Chabner BA
Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
Dhani N; Siu LL
Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-driven patient selection for early clinical trials.
Dienstmann R; Rodon J; Tabernero J
Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
10. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
11. Vascular-disrupting agents in oncology.
Mita MM; Sargsyan L; Mita AC; Spear M
Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
[TBL] [Abstract][Full Text] [Related]
12. Improving the outcomes: developing cancer therapeutics.
Utku N
Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
[TBL] [Abstract][Full Text] [Related]
13. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
14. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
15. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
16. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
18. Modifying phase I methodology to facilitate enrolment of molecularly selected patients.
Hollebecque A; Postel-Vinay S; Verweij J; Demetri GD; Flaherty K; Bedard P; Soria JC
Eur J Cancer; 2013 May; 49(7):1515-20. PubMed ID: 23333057
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapies for malignant gliomas: advances and challenges.
Penas-Prado M; Gilbert MR
Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
